Welcome!

News Feed Item

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Cord Injury Global Clinical Trials Review, H2, 2014" provides data on the Spinal Cord Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Cord Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Cord Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Cord Injury 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Cord Injury 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Spinal Cord Injury Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Spinal Cord Injury 34
May 19, 2014: StemCells Provides Update on Its Phase I/II Study in Spinal Cord Injury 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Pfizer Inc. 35
Clinical Trial Overview of Pfizer Inc. 35
Acorda Therapeutics, Inc. 36
Clinical Trial Overview of Acorda Therapeutics, Inc. 36
Allergan, Inc. 37
Clinical Trial Overview of Allergan, Inc. 37
Stem Cell Sciences UK Ltd 38
Clinical Trial Overview of Stem Cell Sciences UK Ltd 38
Neuralstem, Inc. 39
Clinical Trial Overview of Neuralstem, Inc. 39
BioAxone BioSciences Inc. 40
Clinical Trial Overview of BioAxone BioSciences Inc. 40
AOSpine International 41
Clinical Trial Overview of AOSpine International 41
K-Stemcell Co., Ltd. 42
Clinical Trial Overview of K-Stemcell Co., Ltd. 42
Daiichi Sankyo Company, Limited 43
Clinical Trial Overview of Daiichi Sankyo Company, Limited 43
Bayer AG 44
Clinical Trial Overview of Bayer AG 44
Clinical Trial Overview of Top Institutes / Government 45
U.S. Department of Veterans Affairs 45
Clinical Trial Overview of U.S. Department of Veterans Affairs 45
University of Miami 48
Clinical Trial Overview of University of Miami 48
University of Washington 49
Clinical Trial Overview of University of Washington 49
National Institute of Neurological Disorders and Stroke 50
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 50
University of British Columbia 51
Clinical Trial Overview of University of British Columbia 51
Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
China Spinal Cord Injury Network 53
Clinical Trial Overview of China Spinal Cord Injury Network 53
National Taiwan University Hospital 54
Clinical Trial Overview of National Taiwan University Hospital 54
James J. Peters Veterans Affairs Medical Center 55
Clinical Trial Overview of James J. Peters Veterans Affairs Medical Center 55
University of California, Irvine 56
Clinical Trial Overview of University of California, Irvine 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 106

List of Tables

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Spinal Cord Injury Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Spinal Cord Injury Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 35
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 36
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 37
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Stem Cell Sciences UK Ltd, 2014* 38
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralstem, Inc., 2014* 39
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by BioAxone BioSciences Inc., 2014* 40
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by AOSpine International, 2014* 41
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by K-Stemcell Co., Ltd., 2014* 42
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 43
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 44
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 45
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2014* 48
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 49
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 50
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 51
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 52
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by China Spinal Cord Injury Network, 2014* 53
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 54
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by James J. Peters Veterans Affairs Medical Center, 2014* 55
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 56

List of Figures

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 105

To order this report: Spinal Cord Injury Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
TechTarget storage websites are the best online information resource for news, tips and expert advice for the storage, backup and disaster recovery markets. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies' information technology needs. By understanding these buyers' content consumption behaviors, TechTarget creates the purchase inte...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...